{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000078","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.259170+00:00","generated_at":"2026-06-09T22:16:05.034542+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ligand acquires 13% interest in soticlestat royalties and milestones from Ovid for $30M","bullets":["Ligand will pay Ovid $30M for a 13% interest in all royalties and milestones owed to Ovid on soticlestat.","Soticlestat is in Phase 3 trials for Lennox-Gastaut and Dravet syndromes; Takeda expects regulatory filing in FY2024 (Apr 2024-Mar 2025).","Ovid eligible for up to $660M in milestones plus tiered royalties (low double-digits to 20%) on global sales if approved.","Takeda bears all development costs; Ovid has no ongoing obligations or costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000078","json":"https://secwatch.observer/filing/0000886163-23-000078.json","markdown":"https://secwatch.observer/filing/0000886163-23-000078.md","text":"https://secwatch.observer/filing/0000886163-23-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000078/0000886163-23-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000078/lgnd-20231018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:16:05.034542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}